Agenus Stock Price, News & Analysis

Agenus (NASDAQ: AGEN) announced its participation in the ASCO 2023 Annual Meeting from June 2-6 in Chicago, IL, where it will present clinical data from key trials. An oral presentation on June 5 will detail a Phase 2 trial of balstilimab and zalifrelimab combined with doxorubicin for advanced sarcomas. Additionally, a poster discussion on June 3 will cover the monotherapy results of AGEN2373, a CD137 agonist, in advanced solid tumors. Abstracts will be available on May 25. Balstilimab and zalifrelimab are designed to enhance immune response against cancer, while AGEN2373 targets T and NK cells with reduced liver toxicity risks.

Agenus (NASDAQ: AGEN), an immuno-oncology company, will release its first-quarter 2023 financial results on May 9, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss results and corporate updates. The call can be accessed via dial-in or a live webcast from the Company’s events page. Agenus is focused on developing therapies that leverage the immune system for cancer treatment, utilizing various therapeutics, including antibody agents and cell therapies. The Company aims to expand the reach of cancer immunotherapy by pursuing a range of combination therapies. For more information, visit their website.

Agenus (NASDAQ: AGEN), an immuno-oncology company, will feature Chairman and CEO Dr. Garo Armen at two upcoming investor conferences. The HC Wainwright BioConnect Investor Conference is set for May 2, 2023, at 3:30 PM ET in New York City, where Dr. Armen will participate in a fireside chat. Additionally, he will engage in 1x1 meetings at the EF Hutton Global Conference on May 10, 2023. A live webcast of the fireside chat will be available on the company’s website, with a replay posted afterward. Agenus aims to improve cancer treatment through innovative therapies that enhance the immune response. The company operates advanced antibody discovery platforms and a GMP manufacturing facility to support clinical programs.

Agenus Inc. (NASDAQ: AGEN) has received Fast Track Designation from the FDA for its combination therapy of botensilimab (AGEN1181) and balstilimab (AGEN2034) targeting non-MSI-H colorectal cancer patients. This designation is significant for heavily pretreated patients who have limited treatment options. The ongoing Phase 2 trial aims to show better effectiveness than current standards. Positive results from earlier trials revealed a 23% overall response rate and a 63% 12-month survival rate, significantly outperforming existing treatments. Dr. Steven O’Day highlighted the unmet medical need and the potential for Priority Review from the FDA. Moreover, the company is advancing research in various solid tumor indications.

Agenus has declared a dividend of 5 million shares of its subsidiary, MiNK Therapeutics, to shareholders on record as of April 17, 2023. The distribution aims to provide additional value and direct ownership in MiNK, which is engaged in developing allogeneic T cell therapies for cancer. The shares will be distributed no earlier than April 27, 2023, and no later than May 17, 2023. Fractional shares will be compensated in cash based on MiNK's closing price on the record date. This initiative reflects Agenus' confidence in MiNK's solid tumor programs and its commitment to enhancing shareholder value.

Agenus (NASDAQ: AGEN) announced promising results from a Phase 1b study on botensilimab, a CTLA-4 antibody, combined with balstilimab, a PD-1 antibody, targeting recurrent platinum-resistant ovarian cancer. Presenting at the SGO 2023 Annual Meeting, the study reported a remarkable 33% overall response rate with 67% disease control among 24 evaluable patients. This efficacy surpasses past PD-(L)1/CTLA-4 combinations that showed only 3-10% response rates. The patients involved were heavily pre-treated, suggesting the combination's transformative potential. Agenus is expanding its clinical trials further across various cancer types.

Agenus Inc. provided a corporate update and reported Q4 and full year 2022 financial results, highlighting its lead asset, botensilimab, which has shown promising overall response rates in various cancers. Key results include a 23% response rate in microsatellite stable colorectal cancer and 50% in PD-(L)1 refractory non-small cell lung cancer. A confirmatory Phase 3 trial for MSS CRC is planned for 2023. The company announced existing collaborations could yield $2.7B in milestones and royalties. However, Agenus reported a net loss of $74 million for Q4, totaling $231 million for the year, alongside a cash balance of $193 million.

Agenus has announced the cancellation of its conference call scheduled for March 13, 2023, regarding its minority cash holdings at Silicon Valley Bank (SVB). This decision follows the government's announcement concerning access to SVB deposits. Agenus is a clinical-stage immuno-oncology company focused on developing therapies that enhance the body's immune response against cancer and infections. The company's approach includes a wide array of antibody therapeutics and adoptive cell therapies. Headquartered in Lexington, MA, Agenus continues to aim for innovative cancer treatment solutions.

Agenus (Nasdaq: AGEN), a clinical-stage immuno-oncology company, has announced a conference call scheduled for March 13, 2023, at 8:30 a.m. ET. The purpose of the call is to discuss its minority cash holdings at Silicon Valley Bank (SVB). Interested participants can dial in using specific numbers provided in the release. Agenus focuses on developing therapies to enhance the immune system's ability to combat cancer and infections, leveraging its broad range of antibody therapeutics, cell therapies, and adjuvants. The company is headquartered in Lexington, Massachusetts.